Amanta Healthcare

September 1, 2025 – September 3, 2025

GMP Rumors *	₹25
Price	₹120 - ₹126
Lot size	119
Allotment	Sep 4, 2025
Listing	Sep 8, 2025

📌 Amanta Healthcare IPO Lot Distribution

Category	Lot(s)	Quantity	Amount (₹)	Reserved
Retail	1	119	14,994	29,412
sHNI	14	1,666	2,09,916	300
bHNI	67	7,973	10,04,598	600

📌 Reservation Details

Category	Shares Offered	% Allocation
QIB	50,00,000	50%
HNI	15,00,000	15%
Retail	35,00,000	35%
Total	1,00,00,000	100%

📌 IPO Details

Particulars	Details
Total Issue Size	1,00,00,000 shares (₹126 Cr)
Fresh Issue	1,00,00,000 shares (₹126 Cr)
Issue Type	Book Building IPO
Listing At	BSE, NSE
Pre-Issue Shareholding	2,88,29,351 shares
Post-Issue Shareholding	4,13,29,351 shares

📌 IPO Reservation (as per SEBI rule)

Investor Category	Shares Offered
QIB	Not more than 50%
Retail	Not less than 35%
NII	Not less than 15%

📌 Key Performance Indicators (KPI)

KPI	FY25	FY24	FY23
ROE	12.42%	5.27%	-3.27%
ROCE	13.72%	12.76%	12.19%
Debt/Equity	2.02	3.10	3.43

📌 Company Financials (₹ in Crore)

Particulars	Mar-25	Mar-24	Mar-23
Assets	381.76	352.12	374.06
Total Income	276.09	281.61	262.70
Profit After Tax	10.50	3.63	-2.11
EBITDA	61.05	58.76	56.31
Net Worth	96.39	66.29	62.88
Reserves & Surplus	67.56	39.46	36.05
Total Borrowing	195.00	205.23	215.66

Amanta Healthcare IPO Review – Company Profile, Strengths, and Weakness

Peer Comparison

About Amanta Healthcare Ltd

Incorporation: December 1994
Industry: Pharmaceuticals & Medical Devices
Core Specialization: Development, manufacturing, and marketing of sterile liquid products, with a primary focus on parenteral formulations.

Key Technologies

Amanta Healthcare leverages advanced manufacturing technologies, including:

-----> Aseptic Blow-Fill-Seal (ABFS)

-----> Injection Stretch Blow Moulding (ISBM)

Product Portfolio

Pharmaceutical Products

Fluid therapy formulations (IV fluids, diluents)

-----> Ophthalmic solutions

-----> Respiratory care products

Medical DevicesIrrigation solutions

-----> First-aid products

-----> Eye lubricants

Business Operations

Amanta Healthcare operates through three main business units:
➡ National Sales
➡ International Sales
➡ Product Partnering (collaborations with Indian and global pharmaceutical companies)

The company manufactures 45+ generic pharmaceutical products, marketed under its own brands in India through a strong network of 189 distributors and stockists.

Global Presence

----> Products registered in 19 countries

----> Exports branded products to Africa, Latin America, and the UK

----> Fully compliant with international regulatory standards

Strengths of Amanta Healthcare

Rising Healthcare Awareness: Increasing access to healthcare services, medicines, and insurance in India is fueling demand for pharmaceuticals.

Government Support: Favorable schemes such as the PLI scheme, tax benefits, and infrastructure subsidies are driving sector growth.

Skilled Workforce: India’s large pool of scientists, researchers, and engineers enhances the company’s pharmaceutical research and manufacturing capabilities.

Weaknesses of Amanta Healthcare

Single Manufacturing Facility Risk: Heavy dependence on a single Gujarat facility increases vulnerability to power cuts, accidents, or natural calamities.

Production & Quality Challenges: Any delay, quality issue, or failure to deliver products on time could lead to order cancellations and loss of distributors/clients.

Litigation Risk: Ongoing material litigations could impact the company’s financials, reputation, and long-term growth strategy.

✅ With its global footprint, advanced technology adoption, and strong demand outlook, Amanta Healthcare stands as a promising pharmaceutical company. However, risks like dependence on one facility and litigation exposure are critical factors investors must analyze before applying for the IPO.